Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes

AIDS Rev. 2006 Apr-Jun;8(2):98-107.


The impact of HIV-1 subtype on clinical outcome following exposure to antiretroviral therapy is currently not well known. Natural polymorphisms are often present in HIV-1 non-B subtypes at positions known to be associated with drug resistance in clade B viruses. These changes might influence the emergence of drug-resistant viruses, modifying drug susceptibility and/or the virus replicative capacity. Moreover, different pathways may lead to drug resistance according to HIV-1 clade. Finally, the influence of subtype on the performance of phenotypic assays and in the interpretation of algorithms for genotypic resistance is currently a matter of debate. All these aspects explain why the response to antiretroviral therapy might vary in subjects infected with different HIV-1 clades.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use*
  • Drug Resistance, Viral*
  • Genetic Variation
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV-1 / classification*
  • HIV-1 / drug effects
  • HIV-1 / genetics
  • Humans
  • Reverse Transcriptase Inhibitors / pharmacology
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Treatment Outcome


  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors